Skip to content
Tenfell
Awarded contract
Published 17 Sep 2021

NHS Framework Agreement, Branded Medicines for London and South of England

NHS England · London

Key facts

Awarded
18 Aug 2021
Contract starts
31 Aug 2021
Contract ends
31 Aug 2023
Procedure
Open procedure (above threshold)
Buyer type
Central government

Awarded to 42 suppliers

SupplierValue
Takeda UK Limited—
CST Pharma Ltd—
Dr Reddy's Laboratories (UK) Ltd—
Janssen-Cilag Ltd—
Pfizer Ltd—
Teva UK Ltd—
Bayer plc—
Amgen Ltd—
Aventis Pharma Ltd T/A Sanofi—
Napp Pharmaceuticals—
Sandoz Ltd—
Thornton & Ross Ltd—
Accord-UK Ltd—
AstraZeneca—
Biogen—
Celltrion Healthcare United Kingdom Limited—
Eli Lilly & Company Ltd—
Gedeon Richter UK Ltd—
Gilead Sciences Limited—
Ipsen—
Merck Serono Limited—
Merck Sharpe & Dohme (UK) Limited—
Mylan—
Novo Nordisk—
Organon Pharmaceuticals UK Ltd—
Roche Products Ltd—
Sobi (Swedish Orphan Biovitrum Ltd)—
Zentiva Pharma UK Ltd—
Ferring Pharmaceuticals Limited—
Pharmacosmos UK Ltd—
Vifor Pharma UK Limited—
Merz—
Bristol Myers Squibb—
Morningside Pharmaeuticals—
Tetris Pharma Lts—
Allergan Limited—
UL Global Pharma—
Techdow Pharma England Ltd—
Daiichi Sankyo UK Ltd—
Profile Pharma Ltd—
Chugai—
UCB—

Description

NHS Framework Agreement, Branded Medicines for London and South of England

Offer reference number: CM/PHR/20/5598

FIND A TENDER (FTS) Reference number: FTS-002229

CM/PHR/20/5598/01 - NHS Framework for LONDON Branded Medicines - Tranche B. Period of framework: 1 September 2021 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/20/5598/02 - NHS Framework for the LONDON Branded Medicines - Annual Tranche. Period of framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

CM/PHR/20/5598/03 - NHS Framework for the SOUTH of England Tranche A. Period of Framework: 1 September 2021 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/20/5598/04- NHS Framework for SOUTH of England - Tranche B. Period of framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

CM/PHR/20/5598/05 - NHS Framework for the SOUTH of England Annual Tranche. Period of Framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

CM/PHR/20/5598/06 - NHS Framework for the Midlands & East and North of England Regions - Bevacizumab Period of Framework: 1 September 2021 to 28 February 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 6 months

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.